Clinical Trials
18 trialsNCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT04724460 2025-03-11
ONCO PE
Kyoto University, Graduate School of Medicine
Phase 4 Completed
NCT03895502 2023-10-04
ONCO DVT
Kyoto University, Graduate School of Medicine
Phase 4 Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT01999179 2022-05-18
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
Medical College of Wisconsin
Phase NA Completed
NCT04709510 2021-01-14
Short-term Perioperative Thromboprophylaxis After Major Abdominal Surgery
Istanbul Medeniyet University
Phase NA Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT02334007 2018-09-18
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
McMaster University
Phase 1/2 Completed
NCT01524653 2018-07-10
DISOLVE
University of Vermont
Phase 2 Completed
NCT02581176 2018-06-26
CAP
University Hospital, Akershus
Phase 4 Completed
NCT00312013 2017-03-23
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00966277 2016-12-12
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00259662 2016-12-01
High-dose Periop Statins for Prevention of DVT
Yale University
Phase NA Completed
NCT00773448 2015-07-07
SOME
Ottawa Hospital Research Institute
Phase NA Completed
NCT00967148 2014-10-22
PERI-OP
Ottawa Hospital Research Institute
Phase NA Completed
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed